[go: up one dir, main page]

MX2012000376A - Matrix carrier compositions, methods and uses. - Google Patents

Matrix carrier compositions, methods and uses.

Info

Publication number
MX2012000376A
MX2012000376A MX2012000376A MX2012000376A MX2012000376A MX 2012000376 A MX2012000376 A MX 2012000376A MX 2012000376 A MX2012000376 A MX 2012000376A MX 2012000376 A MX2012000376 A MX 2012000376A MX 2012000376 A MX2012000376 A MX 2012000376A
Authority
MX
Mexico
Prior art keywords
matrix carrier
methods
carrier compositions
nanoparticles
solid phase
Prior art date
Application number
MX2012000376A
Other languages
Spanish (es)
Other versions
MX340134B (en
Inventor
Alexander Vol
Orna Bova
Original Assignee
Oshadi Drug Administration Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oshadi Drug Administration Ltd filed Critical Oshadi Drug Administration Ltd
Publication of MX2012000376A publication Critical patent/MX2012000376A/en
Publication of MX340134B publication Critical patent/MX340134B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided is a matrix carrier composition for use in pharmaceutical delivery system, the composition comprising an intermolecular association of at least a first solid phase comprising nanoparticles having hydrophobic surface, wherein the size of the nanoparticles is in the range of about 5-1000 nm, a second solid phase, comprising a biopolymer having hydrophilic and hydrophobic parts, and a continuous phase comprising oil associated with the first and said second solid phases.
MX2012000376A 2009-07-09 2010-07-08 Matrix carrier compositions, methods and uses. MX340134B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22410009P 2009-07-09 2009-07-09
PCT/IL2010/000551 WO2011004376A1 (en) 2009-07-09 2010-07-08 Matrix carrier compositions, methods and uses

Publications (2)

Publication Number Publication Date
MX2012000376A true MX2012000376A (en) 2012-02-28
MX340134B MX340134B (en) 2016-06-28

Family

ID=43428853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000376A MX340134B (en) 2009-07-09 2010-07-08 Matrix carrier compositions, methods and uses.

Country Status (14)

Country Link
US (2) US9060932B2 (en)
EP (1) EP2451442A4 (en)
CN (2) CN102099011B (en)
AU (1) AU2010269815B2 (en)
BR (1) BR112012000379A2 (en)
CA (1) CA2767342C (en)
IL (1) IL249939A0 (en)
IN (1) IN2012DN00311A (en)
MX (1) MX340134B (en)
NZ (1) NZ597326A (en)
RU (1) RU2528895C2 (en)
SG (2) SG10201403918RA (en)
WO (1) WO2011004376A1 (en)
ZA (1) ZA201109321B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
NZ597326A (en) * 2009-07-09 2013-05-31 Oshadi Drug Administration Ltd Matrix carrier compositions, methods and uses
RU2532032C1 (en) * 2013-03-21 2014-10-27 Сергей Алексеевич Успенский Solid-phase method of producing water-soluble bioactive nanocomposite based on melanin-modified hyaluronic acid salt and gold nanoparticles
RU2544166C2 (en) * 2013-05-14 2015-03-10 Александр Александрович Кролевец Method of producing zinc oxide microcapsules
US9168211B2 (en) * 2014-03-28 2015-10-27 Johnson & Johnson Consumer Inc. Method of making an anhydrous, pigmented composition
US10398732B2 (en) 2016-10-13 2019-09-03 Marshall University Research Corporation Compositions and methods for treating striated muscle injury, treating striated muscle atrophy and/or for promoting striated muscle growth
CN108451787B (en) * 2018-05-23 2020-01-07 上海格兰化妆品有限公司 Vitamin A alcohol-embedded nano lipid carrier and preparation method thereof
US12263252B2 (en) 2019-06-05 2025-04-01 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
CN115389659B (en) * 2022-08-23 2024-07-16 浙江中医药大学 Cell membrane bonded magnetic carbon sphere composite material and preparation method and application thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
ES2027518A6 (en) 1990-12-18 1992-06-01 Andromaco Lab A process for preparing new non-covalent polysaccharide-protein associations having pharmacological activity.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US20040018236A1 (en) 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
ES2093562B1 (en) 1995-05-26 1997-07-01 Univ Santiago Compostela STABILIZATION OF COLLOID SYSTEMS THROUGH FORMATION OF LIPIDO-POLISACARIDO IONIC COMPLEXES.
US6071535A (en) 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6322765B1 (en) 1996-02-15 2001-11-27 Wacker-Chemie Gmbh Process for preparing silicon dioxide
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
FR2767718B1 (en) * 1997-08-28 1999-10-22 Oreal WATER-IN-OIL EMULSION INCLUDING PYROGENATED SILICA AND POLYSACCHARIDE ALKYLETHER
HU225069B1 (en) 1997-09-09 2006-06-28 Lyotropic Therapeutics Coated particles, methods of making and using
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
FR2773804B1 (en) 1998-01-19 2000-02-18 Sanofi Sa SYNTHESIS POLYSACCHARIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
BR0009437A (en) 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Pre-gelatinized starch in a controlled release formulation
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7195780B2 (en) 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
DE10001172A1 (en) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templating solid particles with polymer multilayers
JP4631119B2 (en) 2000-01-28 2011-02-16 Ｊｓｒ株式会社 Method for producing hydrophobized colloidal silica
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6548264B1 (en) 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
AU7315301A (en) 2000-06-29 2002-01-14 Emisphere Tech Inc Compounds and compositions for delivering active agents
ATE320267T1 (en) * 2000-08-11 2006-04-15 Lohmann Animal Health Gmbh W/O EMULSION ADJUVANT COMPOSITIONS FOR VACCINES
US20020150621A1 (en) 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for drug delivery
FR2819720B1 (en) 2001-01-22 2004-03-12 Fournier Lab Sa NEW FENOFIBRATE TABLETS
US6698247B2 (en) 2001-05-04 2004-03-02 Corning Incorporated Method and feedstock for making silica by flame combustion
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
IL162183A0 (en) 2001-12-21 2005-11-20 Celator Technologies Inc Polymer-lipid delivery vehicles and methods for the preparation thereof
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
AU2003210477A1 (en) 2002-01-09 2003-07-30 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
WO2003066859A2 (en) 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
US7244498B2 (en) 2002-06-12 2007-07-17 Tda Research, Inc. Nanoparticles modified with multiple organic acids
US7090868B2 (en) 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
JP5452843B2 (en) 2003-01-06 2014-03-26 エミスフィアー テクノロジーズ インコーポレイテッド Nocturnal oral insulin treatment
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
JP2007523050A (en) 2003-09-17 2007-08-16 カイアズマ・リミテッド Composition that can facilitate permeation through biological barriers
CA2541445A1 (en) 2003-10-31 2005-05-12 Teva Pharmaceutical Industries Ltd. Nanoparticles for drug delivery
KR100638041B1 (en) 2003-12-24 2006-10-23 주식회사 삼양사 Nanoparticle composition for oral administration of water-soluble drug and preparation method thereof
EP1742663A2 (en) 2004-04-15 2007-01-17 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US7288134B2 (en) 2004-09-10 2007-10-30 International Business Machines Corporation Dumbbell-like nanoparticles and a process of forming the same
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20060083781A1 (en) 2004-10-14 2006-04-20 Shastri V P Functionalized solid lipid nanoparticles and methods of making and using same
WO2006062506A1 (en) 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
US7923682B2 (en) 2005-08-09 2011-04-12 University Of Sunderland Fingerprint analysis using mass spectrometry
DK1945271T3 (en) * 2005-10-24 2020-01-13 Magsense Life Sciences Inc Process for the preparation of polymer-coated microparticles
US20070104778A1 (en) 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20070258889A1 (en) * 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
US20070134332A1 (en) 2005-11-21 2007-06-14 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
MX2008013165A (en) 2006-04-12 2009-01-29 Biodel Inc Rapid acting and long acting insulin combination formulations.
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
EP2232123B1 (en) 2008-01-11 2014-09-17 PII Limited Pipeline inspection apparatus and method using two different ultrasound wavemodes
NZ597326A (en) * 2009-07-09 2013-05-31 Oshadi Drug Administration Ltd Matrix carrier compositions, methods and uses

Also Published As

Publication number Publication date
IL249939A0 (en) 2017-03-30
CN102099011B (en) 2016-06-01
US9060932B2 (en) 2015-06-23
AU2010269815B2 (en) 2015-10-15
BR112012000379A2 (en) 2016-03-29
CA2767342A1 (en) 2011-01-13
CA2767342C (en) 2018-05-01
EP2451442A4 (en) 2014-02-12
CN105997864A (en) 2016-10-12
EP2451442A1 (en) 2012-05-16
US9504648B2 (en) 2016-11-29
ZA201109321B (en) 2013-02-27
RU2528895C2 (en) 2014-09-20
NZ597326A (en) 2013-05-31
US20150245993A1 (en) 2015-09-03
SG177536A1 (en) 2012-03-29
CN102099011A (en) 2011-06-15
US20120100216A1 (en) 2012-04-26
WO2011004376A1 (en) 2011-01-13
AU2010269815A1 (en) 2012-01-19
MX340134B (en) 2016-06-28
SG10201403918RA (en) 2014-10-30
RU2012104554A (en) 2013-08-20
IN2012DN00311A (en) 2015-05-08

Similar Documents

Publication Publication Date Title
MX340134B (en) Matrix carrier compositions, methods and uses.
MX2010004366A (en) Water-immiscible materials as vehicles for drug delivery.
WO2010008445A3 (en) Branched pha compositions, methods for their production, and use in applications
WO2012034079A3 (en) Macrolide dosage forms
WO2011081430A3 (en) Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
EP2195377B8 (en) High polymer content hybrid drag reducers
ZA200800818B (en) Plant support formulation, vehicle for the delivery and translocation of phytologically beneficial substances and compositions containing same
WO2011060353A3 (en) Lattice-mismatched core-shell quantum dots
IL208937A0 (en) Cell binding agent cytotoxic drug conjugates, compositions comprising the same and uses thereof
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
MX336823B (en) Ambient cure solvent-based coatings for writable-erasable surfaces.
NZ600725A (en) Methods and compositions for delivery of nucleic acids
WO2011138678A3 (en) Compositions, gels and foams with rheology modulators and uses thereof
WO2010096733A3 (en) Luminescent porous silicon nanoparticles, methods of making and using same
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
TN2010000152A1 (en) Pharmaceutical compositions
WO2009134389A9 (en) An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
EP2488023A4 (en) Antimicrobial composition
MX2009007774A (en) Ophthalmic compositions containing a synergistic combination of three polymers.
WO2013169506A3 (en) Composition for application to the skin comprising silsesquioxane resin wax and solid particulate
SG163487A1 (en) Ambient cure water-based coatings for writable- erasable surfaces
WO2010005732A8 (en) Composition and method of preparation of release systems for constant (zero-order) release of active agents
MX2012006515A (en) Polymeric hybrid organometalloglass.
TW200641025A (en) Reverse phase hydrophilic polymers and their use in water-expandandable elastomeric compositions
EP2245091A4 (en) Nanoparticle dispersion, compositions containing the same, and articles made therefrom

Legal Events

Date Code Title Description
FG Grant or registration